Full Press Release Details
Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
increasing demand for needed treatments designed for women, Dar is taking action to make its proprietary Sildenafil Cream formulation
available via prescription this year
Enables women to access a solution that they want and need
Creates an opportunity to accelerate revenue generation from this proprietary formulation
Dar expects to start recording revenue and cash flow in the 4th quarter of this year
call today at 4:30 p.m. ET to discuss the expanded business strategy to integrate 503B compounding as part of a dual-path approach to
bring select Dar proprietary formulations to market as soon as practicable
DIEGO, March 31, 2025 (GLOBE NEWSWIRE) - Dare Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission
to challenge the status quo, making women's health a priority, today reported financial results for the year ended December 31,
2024 and provided a company update.
exists to accelerate innovation in women's health and our goal is to fulfill the urgent need for access to evidence-based treatment
options. We are proud to announce that we are taking action to make our proprietary Sildenafil Cream formulation available via prescription
this year as a compounded drug under Section 503B of the FDCA, because we believe women should not have to wait for access to our formulation
when an alternative legal path via Section 503B is available while we continue to pursue FDA approval of Sildenafil Cream as a treatment
for female sexual arousal disorder. Our proprietary formulation would be produced by a 503B-registered outsourcing facility partner,
which is registered with the FDA, subject to FDA inspections and subject to quality standards, including compliance with cGMP regulations,"
said Sabrina Martucci Johnson, President and CEO of Dar Bioscience. "After urging on the part of the healthcare community
and hearing the demand from women, we are targeting making our proprietary Sildenafil Cream formulation available via one 503B-registered
outsourcing facility partner in the fourth quarter of 2025."
believe the diversity of our portfolio, the progress we are making in advancing our product candidates, and the revenue opportunity from
our proprietary Sildenafil Cream formulation based on our announcement today, puts Dar on track for meaningful milestones in
2025," said Ms. Johnson.
Cream and 503B Compounding
providers and women are seeking a formulation of sildenafil that they can trust. Based on the study published in 2024 I am very
excited about the availability of Dar 's Sildenafil Cream formulation as an on demand' solution for women,"
stated Dr. Sheryl Kingsberg, Division Chief of Behavioral Medicine, Department of OBGYN, University Hospitals Cleveland Medical Center,
Ohio, and Past President of The International Society for the Study of Women's Sexual Health, as well as co-editor of the Textbook
of Female Sexual Function and Dysfunction: Diagnosis and Treatment. "I am thrilled that Dar is taking action to deliver
this science-backed formulation-with product consistency from a 503B-registered outsourcing facility, complete toxicology studies,
and randomized placebo-controlled studies-to the women who need it without delay."
is the case with men, decreased genital blood flow can also compromise a woman's ability to have a pleasurable sexual experience.
In January 2020 we published study findings demonstrating that Dar 's Sildenafil Cream elicits a quantifiable, rapid
genital response in women within 10-15 minutes using thermography to assess genital temperature changes, a surrogate for genital blood
flow," stated Dr. Irwin Goldstein, the director of San Diego Sexual Medicine and President of The Institute for Sexual Medicine,
Inc., and an expert considered a founder of the field of sexual medicine, having been involved with sexual dysfunction research since
the late 1970 s and renowned for his work regarding erectile dysfunction as well as female sexual dysfunction. "It is encouraging
that Dar is taking action to make this formulation available later this year for the women who need it."
is committed to a strategy that optimizes for access to solutions in a fiscally responsible manner. We plan to focus our resources on
provider-to-provider education about disease state and our proprietary formulation and do not anticipate needing to invest more than
$1 million to support the activities required to make our Sildenafil Cream formulation available via a partner 503B-registered outsourcing
facility. We expect to start recording revenue and cash flow in the 4th quarter of this year. We are targeting the second quarter of
2025 to provide an update on the strategic partnerships to achieve these objectives," added Ms. Johnson. "Like Sildenafil
Cream, there are other proprietary formulations in the Dar portfolio that could also be provided via a prescription through the
FDA's 503B framework. We are actively evaluating a dual-path approach for some of our other proprietary formulations as part of
our responsibility to women, to the healthcare community, and to our shareholders. In addition, we may also bring to market consumer
health products that can be obtained without a physician's prescription. We are also targeting the second quarter of 2025 to provide
an update on timing and strategic partnerships to achieve these objectives."
Highlights and Anticipated 2025 Milestones - Therapeutic Development Pipeline Highlights
a novel, investigational hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement
with Bayer HealthCare.
Cream, 3.6%, a proprietary, investigational cream formulation of sildenafil, the active ingredient in Viagra , for topical
on-demand administration to treat female sexual arousal disorder (FSAD).
| Continued operational progress toward a planned Phase 3 study, including constructive discussions with FDA; Phase 3 design, development, and collaboration strategy updates expected throughout 2025. | |
| In December 2024, Dar announced plans for a Phase 3 study of Sildenafil Cream reflecting FDA feedback for safety and efficacy evaluations to support the indication of treatment of FSAD in premenopausal women. | |
| Dar plans to submit the protocol and statistical analysis plan for an adequate and well-controlled Phase 3 clinical study, reflecting the FDA's recommendations, to the FDA in the second quarter of 2025, pending review of additional forthcoming recommendations from the FDA that impact Dar 's statistical analysis plan. |
a proprietary, fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert for the treatment of human papillomavirus
(HPV)-related cervical diseases.
| Conducting activities necessary to enable submission of an IND application to the FDA for a Phase 2, randomized, placebo-controlled, double-blind clinical study of DARE-HPV for clearance of high-risk HPV infection in women. | |
| Supported with up to $10 million milestone-based non-dilutive award announced October 2024. |
an investigational proprietary formulation of tamoxifen for intravaginal administration being developed as a hormone-free alternative
to estrogen-based therapies for the treatment of moderate-to-severe dyspareunia, or pain during sexual intercourse.
an investigational intravaginal ring designed to deliver bio-identical progesterone continuously for up to 14 days for the prevention
| Conducting activities necessary to enable the IND and a Phase 1 clinical study. | |
| Supported by a $2 million grant from NICHD. | |
| A Phase 1 study would also serve to support safety and PK for this progesterone intravaginal ring to also be investigated for luteal phase support as part of an IVF regimen. |
S, an investigational biodegradable contraceptive implant. Casea S is designed to control release of a well-characterized contraceptive,
etonogestrel, for a set period of time (18-24 months) before dissolving.
| It is designed to provide women with a long-acting, minimally-invasive contraceptive method that will not require surgical removal by a healthcare provider, which would improve convenience and could eliminate one of the barriers to use associated with existing implanted contraceptives. | |
| Casea S is being tested in a single-center, two-part Phase 1 clinical study to evaluate the PK of etonogestrel, removability, safety, and tolerability of Casea S pellets inserted subdermally in healthy women of reproductive age (ClinicalTrials.gov ID: NCT05174884). | |
| The ongoing Phase 1 study is being conducted by FHI 360, a nonprofit organization, with support from a foundation grant. There are no development costs to Dar at this time. | |
| Casea S was recently acquired by Theramex. In February 2025, Dar entered into a co-development and licensing agreement with Theramex for the development of Casea S in the U.S. If Dar determines that the results from the Phase 1 study are positive and elects to proceed with development, Dar would be responsible for conducting a Phase 2 study in the U.S. In accordance with the agreement, the costs of such Phase 2 study would be shared by Dar and Theramex on terms to be agreed upon, taking into account the size of the opportunity for Casea S in the respective markets. |
a novel, long-acting, reversible personal contraceptive implant delivering levonorgestrel with a woman-centered design that has the
potential to be a long-acting, yet convenient and user-controlled contraceptive option; development supported with an up to $49 million
| DARE-LARC1's woman-centered design seeks to offer the benefits of traditional long-acting reversible contraceptives with the added flexibility and convenience for the user to pause and resume release of levonorgestrel, depending on her desire for fertility or contraceptive protection. | |
| Under a grant agreement entered into in June 2021, Dar may receive up to approximately $49.0 million, payable over approximately five years, to advance development of the technology through nonclinical proof of principle studies to enable an IND submission. | |
| $3.5 million in grant funding received in 2024, bringing the total received to date to $31.8 million. |
| Cash position: at December 31, 2024, cash and cash equivalents of approximately $15.7 million, and working capital deficit of approximately $3.2 million. | |
| General and administrative expenses: approximately $9.2 million for 2024, which is a 24% decrease compared to the prior year due primarily to reduced commercial readiness expenses and reduced headcount. | |
| Research and development (R&D) expenses: approximately $14.2 million for 2024, which is a 34% decrease compared to the prior year. R&D expenses in 2024 primarily reflected the costs of manufacturing activities and ongoing enrollment in the Phase 3 study of Ovaprene. Currently, Dar 's only active clinical study is the Phase 3 study of Ovaprene. |
encourage investors to review the more detailed discussion of our financial statements, our financial condition, liquidity, capital resources,
and risk factors in our annual report on Form 10-K for the year ended December 31, 2024, filed with the SEC today.
will host a conference call and live webcast today, March 31, 2025, at 4:30 p.m. Eastern Time to review financial results for the year
ended December 31, 2024 and to provide a company update.
access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll free). The conference ID number for the call
is 9767621. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the
company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to
download and install any necessary software. The webcast will be archived in the same section of the company's website and available
for replay until April 14, 2025.
Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. We
believe that innovation does not have to start from scratch. Our goal is to bring to market as soon as practicable innovative evidence-based
solutions that address decades of unmet needs in women's health and enhance outcomes and convenience, primarily in the areas of
contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products we identify,
in many cases, already have clinical proof of concept or existing safety data for the active ingredient that we leverage. This gives
us optionality and flexibility, in many cases, in how we seek to bring solutions to market in ways designed to optimize access for women
in a fiscally responsible manner.
first FDA-approved product to emerge from Dar 's portfolio of women's health product candidates is XACIATO
(clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients
12 years of age and older, which is under a global license agreement with Organon. Visit www.xaciato.com for information about XACIATO.
Dar 's portfolio also includes potential first-in-category candidates in clinical development: Ovaprene , a novel, hormone-free
monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel
cream formulation of sildenafil, the active ingredient in Viagra , to treat female sexual arousal disorder (FSAD); and DARE-HRT1,
a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about Dar 's
full portfolio of women's health product candidates and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
Bioscience leadership has been named on the Medicine Maker's Power List and Endpoints News' Women in Biopharma and Dar 's
CEO has been honored as one of Fierce Pharma's Most Influential People in Biopharma for Dar 's contributions to innovation
and advocacy in the women's health space.
may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors
section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar
will use these channels to distribute material information about the company and may also use social media to communicate important information
about the company, its finances, product and product candidates, clinical trials and other matters. The information Dar posts
on its investor relations website or through social media channels may be deemed to be material information. Dar encourages investors,